Overview

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

Status:
Completed
Trial end date:
2022-01-24
Target enrollment:
Participant gender:
Summary
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812
Phase:
Phase 1
Details
Lead Sponsor:
Cognition Therapeutics
Collaborator:
National Institute on Aging (NIA)